OncoCyte Statistics
Total Valuation
OncoCyte has a market cap or net worth of $75.79 million. The enterprise value is $47.95 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoCyte has 28.60 million shares outstanding. The number of shares has increased by 111.83% in one year.
| Current Share Class | 28.60M |
| Shares Outstanding | 28.60M |
| Shares Change (YoY) | +111.83% |
| Shares Change (QoQ) | +47.82% |
| Owned by Insiders (%) | 13.45% |
| Owned by Institutions (%) | 6.54% |
| Float | 7.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.97 |
| Forward PS | 53.64 |
| PB Ratio | 7.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.34.
| Current Ratio | 3.75 |
| Quick Ratio | 3.57 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | -237.73 |
Financial Efficiency
Return on equity (ROE) is -428.96% and return on invested capital (ROIC) is -85.78%.
| Return on Equity (ROE) | -428.96% |
| Return on Assets (ROA) | -22.17% |
| Return on Invested Capital (ROIC) | -85.78% |
| Return on Capital Employed (ROCE) | -45.97% |
| Revenue Per Employee | $78,429 |
| Profits Per Employee | -$1.19M |
| Employee Count | 49 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.37% in the last 52 weeks. The beta is 0.99, so OncoCyte's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -0.37% |
| 50-Day Moving Average | 2.97 |
| 200-Day Moving Average | 2.83 |
| Relative Strength Index (RSI) | 36.15 |
| Average Volume (20 Days) | 35,972 |
Short Selling Information
The latest short interest is 265,493, so 0.93% of the outstanding shares have been sold short.
| Short Interest | 265,493 |
| Short Previous Month | 288,176 |
| Short % of Shares Out | 0.93% |
| Short % of Float | 3.42% |
| Short Ratio (days to cover) | 6.44 |
Income Statement
In the last 12 months, OncoCyte had revenue of $3.84 million and -$58.26 million in losses. Loss per share was -$3.34.
| Revenue | 3.84M |
| Gross Profit | 2.09M |
| Operating Income | -23.30M |
| Pretax Income | -36.35M |
| Net Income | -58.26M |
| EBITDA | -21.58M |
| EBIT | -23.30M |
| Loss Per Share | -$3.34 |
Full Income StatementBalance Sheet
The company has $31.03 million in cash and $3.48 million in debt, giving a net cash position of $27.55 million or $0.96 per share.
| Cash & Cash Equivalents | 31.03M |
| Total Debt | 3.48M |
| Net Cash | 27.55M |
| Net Cash Per Share | $0.96 |
| Equity (Book Value) | 10.22M |
| Book Value Per Share | 0.36 |
| Working Capital | 26.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.74 million and capital expenditures -$799,000, giving a free cash flow of -$23.54 million.
| Operating Cash Flow | -22.74M |
| Capital Expenditures | -799,000 |
| Free Cash Flow | -23.54M |
| FCF Per Share | -$0.82 |
Full Cash Flow StatementMargins
| Gross Margin | 54.46% |
| Operating Margin | -606.25% |
| Pretax Margin | -1,514.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -111.83% |
| Shareholder Yield | -111.83% |
| Earnings Yield | -77.17% |
| FCF Yield | -31.18% |
Analyst Forecast
The average price target for OncoCyte is $5.42, which is 104.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.42 |
| Price Target Difference | 104.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
OncoCyte has an Altman Z-Score of -8.41 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.41 |
| Piotroski F-Score | 4 |